淋巴水肿是一种以四肢水肿为特征的衰弱性疾病，纤维脂肪沉积,淋巴管生成受损，和功能失调的淋巴管，常伴有继发于恶性肿瘤治疗的淋巴损伤。新的证据表明，由T细胞调节的免疫功能障碍在淋巴水肿的发展中起着关键作用。具体来说,Th1,Th2,Treg,Th17细胞已被确定为淋巴水肿病理变化的关键调节因子。在这次审查中,我们的目的是概述当前对CD4+T细胞作用的理解，包括Th1,Th2,Treg,和Th17子集，在淋巴水肿的进展中，并讨论针对T细胞炎症的相关疗法来管理淋巴水肿。
Lymphedema is a debilitating disease characterized by extremity edema, fibroadipose deposition, impaired lymphangiogenesis, and dysfunctional lymphatics, often with lymphatic injury secondary to the treatment of malignancies. Emerging evidence has shown that immune dysfunction regulated by T cells plays a pivotal role in development of lymphedema. Specifically, Th1, Th2, Treg, and Th17 cells have been identified as critical regulators of pathological changes in lymphedema. In this
review, our aim is to provide an overview of the current understanding of the roles of CD4+ T cells, including Th1, Th2, Treg, and Th17 subsets, in the progression of lymphedema and to discuss associated therapies targeting T cell inflammation for management of lymphedema.
